Ocrevus (ocrelizumab) / Biogen, Roche  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

13 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ocrevus (ocrelizumab) / Roche
NCT02807285: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

No Longer Available
N/A
US
Ocrelizumab, RO4964913
Genentech, Inc.
Multiple Sclerosis
 
 
NCT04855617: Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

Completed
N/A
122
US
Ocrelizumab, OCREVUS
NYU Langone Health, Genentech, Inc.
Multiple Sclerosis
10/22
10/22
NCT03562975: Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Active, not recruiting
N/A
18
US
Ocrelizumab, Ocrevus
University of South Florida, Genentech, Inc.
Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
02/23
12/23
NCT03396822: Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

Completed
N/A
24
US
Gadoteridol
University of Maryland, Baltimore, Genentech, Inc.
Multiple Sclerosis
05/23
05/23
NCT05627271: The 'Wearing Off' Effect of DMT

Completed
N/A
39
Europe
ocrelizumab, Ocrevus, natalizumab, Tysabri, ofatumumab, Kesimpta
Novartis Pharmaceuticals
Multiple Sclerosis
04/23
04/23
NCT03873389: Ocrelizumab Effects on the Metabolome in MS

Completed
N/A
25
US
Ocrelizumab, Ocrevus
Johns Hopkins University, Genentech, Inc.
Multiple Sclerosis
06/23
12/23
NCT05081700: A Systems Approach to Understanding Disease Processes in Multiple Sclerosis

Active, not recruiting
N/A
14
US
All patients in the study will be treated with ocrelizumab, OCREVUS
Providence Health & Services, Institute for Systems Biology, Genentech, Inc.
Multiple Sclerosis
12/24
12/24
ORATORIO-CP, NCT05974852: Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

Active, not recruiting
N/A
732
US
Ocrelizumab
State University of New York at Buffalo, Genentech, Inc.
Primary Progressive Multiple Sclerosis
11/24
09/25
ORATORIO-Cort, NCT05974839: Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ical)

Active, not recruiting
N/A
732
US
Ocrelizumab
State University of New York at Buffalo, Genentech, Inc.
Primary Progressive Multiple Sclerosis
06/24
09/25
NCT05266469: Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

Recruiting
N/A
240
RoW
Ofatumumab, Ocrelizumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/24
12/24
NCT06121349: WOE of Anti-CD20 Therapies

Recruiting
N/A
150
US
ocrelizumab, Ocrevus, ofatumumab, KESIMPTA
Novartis Pharmaceuticals
Multiple Sclerosis
02/25
02/25
MuSicalE, NCT03593590: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

Active, not recruiting
N/A
1710
Europe, RoW
Ocrelizumab, Ocrevus
Hoffmann-La Roche
Multiple Sclerosis
07/25
07/25
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31

Download Options